AJP - Heart AJP: Endocrinology and Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol (December 1, 2006). doi:10.1152/ajpheart.01072.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/4/H1655    most recent
01072.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szmitko, P. E.
Right arrow Articles by Verma, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szmitko, P. E.
Right arrow Articles by Verma, S.
Submitted on September 30, 2006
Accepted on November 29, 2006

ADIPONECTIN AND CARDIOVASCULAR DISEASE

Paul Edward Szmitko1, Hwee Teoh2, Duncan J Stewart3, and Subodh Verma2*

1 General Internal Medicine, University of Toronto, Toronto, Canada
2 Cardiac Surgery, St. Michael's Hospital, Toronto, Canada
3 Cardiology, St. Michael's Hospital, Toronto, Canada

* To whom correspondence should be addressed. E-mail: subodh.verma{at}sympatico.ca.

The cardiometabolic syndrome, associated with increased cardiovascular disease risk in the industrialized world, is estimated to affect one in four adults. Although the mechanisms linking obesity and cardiovascular disease remain unclear, research continues to unravel the molecular pathways behind this pandemic. Adipose tissue has emerged as a metabolically active participant in mediating vascular complications, serving as an active endocrine and paracrine organ secreting adipokines, which participate in diverse metabolic processes. Among these adipokines is adiponectin, which seems to possess antiatherogenic and antiinflammatory effects and may be protective against cardiovascular disease development. The current review describes the pathophysiology of adiponectin in atherosclerotic disease.




This article has been cited by other articles:


Home page
 ChestHome page
W. Galal, Y. R. B. M. van Gestel, S. E. Hoeks, D. D. Sin, T. A. Winkel, J. J. Bax, H. Verhagen, A. M. M. Awara, J. Klein, R. T. van Domburg, et al.
The Obesity Paradox in Patients With Peripheral Arterial Disease
Chest, November 1, 2008; 134(5): 925 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Cardiovasc DisHome page
C. Schindler
Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.